[S02DA03, antipyrine, The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Epoprostenol.]
[G03XB02, ulipristal, The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ulipristal.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Epoprostenol is combined with Streptokinase.]
[J01GA01, streptomycin, Epoprostenol may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L01AD04, streptozocin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Streptozocin.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01CG01, sulbactam, Epoprostenol may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Sulfamethoxazole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Epoprostenol.]
[M01AB02, sulindac, The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Epoprostenol.]
[M01AX04, apazone, The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Epoprostenol.]
[L01BB02, mercaptopurine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The risk or severity of bleeding can be increased when Tamoxifen is combined with Epoprostenol.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01CB02, teniposide, The risk or severity of bleeding can be increased when Epoprostenol is combined with Teniposide.]
[R03CC03, terbutaline, Terbutaline may decrease the antihypertensive activities of Epoprostenol.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may increase the anticoagulant activities of Epoprostenol.]
[G03BA03, testosterone, Testosterone may increase the anticoagulant activities of Epoprostenol.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05AE05, lurasidone, Lurasidone may decrease the antihypertensive activities of Epoprostenol.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Epoprostenol.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Epoprostenol.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01AC01, thiotepa, The risk or severity of bleeding can be increased when Epoprostenol is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Tioguanine.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Epoprostenol.]
[N05AB08, thioproperazine, Thioproperazine may decrease the antihypertensive activities of Epoprostenol.]
[N05AC02, thioridazine, Thioridazine may decrease the antihypertensive activities of Epoprostenol.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Epoprostenol.]
[N05AL03, tiapride, Epoprostenol may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Epoprostenol.]
[S01ED01, timolol, Epoprostenol may increase the hypotensive activities of Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01AA12, tobramycin, Epoprostenol may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[M02AX02, tolazoline, Epoprostenol may increase the hypotensive activities of Tolazoline.]
[V04CA01, tolbutamide, Tolbutamide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Epoprostenol.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Epoprostenol.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Epoprostenol.]
[N06AX05, trazodone, The risk or severity of bleeding can be increased when Trazodone is combined with Epoprostenol.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Epoprostenol.]
[S01BA05, triamcinolone, The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Trichlormethiazide.]
[A16AX12, trientine, Epoprostenol may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, Trifluoperazine may decrease the antihypertensive activities of Epoprostenol.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[A03AA05, trimebutine, Epoprostenol may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[S01ED04, metipranolol, Metipranolol may increase the hypotensive activities of Epoprostenol.]
[C02BA01, trimethaphan, Epoprostenol may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA06, trimipramine, Trimipramine may decrease the antihypertensive activities of Epoprostenol.]
[N06AX24, vilazodone, Vilazodone may decrease the antihypertensive activities of Epoprostenol.]
[C09CA09, azilsartan medoxomil, Epoprostenol may increase the hypotensive activities of Azilsartan medoxomil.]
[R03DX07, roflumilast, Epoprostenol may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Epoprostenol may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Epoprostenol may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[B01AD04, urokinase, Urokinase may increase the anticoagulant activities of Epoprostenol.]
[S01AA28, vancomycin, Epoprostenol may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Epoprostenol may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Epoprostenol may increase the anticoagulant activities of Rivaroxaban.]
[R03AC18, indacaterol, Indacaterol may decrease the antihypertensive activities of Epoprostenol.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Epoprostenol is combined with Ticagrelor.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Epoprostenol.]
[N06AX09, viloxazine, Epoprostenol may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA01, vinblastine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Vinblastine.]
[C04AX07, vincamine, Epoprostenol may increase the hypotensive activities of Vincamine.]
[L01CA03, vindesine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Vindesine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[A11HA03, vitamin E, Vitamin E may increase the antiplatelet activities of Epoprostenol.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Warfarin.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Epoprostenol.]
[C03BA10, xipamide, Epoprostenol may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Zidovudine.]
[N05AF05, zuclopenthixol, Zuclopenthixol may decrease the antihypertensive activities of Epoprostenol.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[B06AC02, icatibant, Epoprostenol may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Lepirudin.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05AE04, ziprasidone, Ziprasidone may increase the antihypertensive activities of Epoprostenol.]
[G03AC10, drospirenone, The risk or severity of adverse effects can be increased when Drospirenone is combined with Epoprostenol.]
[V03AC02, deferiprone, Epoprostenol may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of bleeding can be increased when Epoprostenol is combined with Alemtuzumab.]
[N02BA01, aspirin, Acetylsalicylic acid may increase the antiplatelet activities of Epoprostenol.]
[L01EJ01, ruxolitinib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Ruxolitinib.]
[G04BD07, tolterodine, Tolterodine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DH04, doripenem, Epoprostenol may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Epoprostenol may increase the hypotensive activities of Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of bleeding can be increased when Epoprostenol is combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, Epoprostenol may increase the hypotensive activities of Rituximab.]
[S01FA01, atropine, Atropine may decrease the antihypertensive activities of Epoprostenol.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[B03XA04, peginesatide, Epoprostenol may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Azacitidine.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01BC05, gemcitabine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Gemcitabine.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[G04BE10, avanafil, Epoprostenol may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Epoprostenol.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Gemtuzumab ozogamicin.]
[A08AA11, lorcaserin, Epoprostenol may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Mirabegron may decrease the antihypertensive activities of Epoprostenol.]
[L01XG02, carfilzomib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Carfilzomib.]
[L02BB04, enzalutamide, Epoprostenol may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[L01EA04, bosutinib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Bosutinib.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Epoprostenol is combined with Defibrotide.]
[C01CA18, octopamine, Octopamine may decrease the antihypertensive activities of Epoprostenol.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Epoprostenol.]
[D02BA02, octinoxate, Epoprostenol may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Bendamustine.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Epoprostenol.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Epoprostenol.]
[C08CA13, lercanidipine, Epoprostenol may increase the hypotensive activities of Lercanidipine.]
[L04AA29, tofacitinib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Tofacitinib.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Epoprostenol.]
[V09IX04, fluorodeoxyglucose F18, Epoprostenol may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Epoprostenol.]
[G04BE03, sildenafil, The risk or severity of hemorrhage can be increased when Epoprostenol is combined with Sildenafil.]
[V08CA11, gadofosveset, Epoprostenol may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Ponatinib.]
[B01AF02, apixaban, Apixaban may increase the anticoagulant activities of Epoprostenol.]
[A16AX08, teduglutide, Epoprostenol may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Epoprostenol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Epoprostenol may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of bleeding can be increased when Epoprostenol is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Epoprostenol.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AA12, ancestim, Epoprostenol may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Epoprostenol.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Epoprostenol.]
[L04AA18, everolimus, The risk or severity of bleeding can be increased when Epoprostenol is combined with Everolimus.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R02AX03, benzydamine, The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Epoprostenol.]
[L01EE01, trametinib, Epoprostenol may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Epoprostenol may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Epoprostenol.]
[C08EA02, bepridil, Epoprostenol may increase the hypotensive activities of Bepridil.]
[C02KX05, riociguat, Epoprostenol may increase the hypotensive activities of Riociguat.]
[A10BJ03, lixisenatide, Epoprostenol may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[A05AA03, cholic acid, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Cholic Acid.]
[C02KX04, macitentan, Epoprostenol may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Epoprostenol.]
[N06AX26, vortioxetine, The risk or severity of bleeding can be increased when Vortioxetine is combined with Epoprostenol.]
[G03AC08, etonogestrel, The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etonogestrel.]
[J05AP08, sofosbuvir, Epoprostenol may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Droxidopa may decrease the antihypertensive activities of Epoprostenol.]
[C07AB04, acebutolol, Epoprostenol may increase the hypotensive activities of Acebutolol.]
[N05CH03, tasimelteon, Epoprostenol may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Epoprostenol may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Epoprostenol may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S01ED02, betaxolol, Epoprostenol may increase the hypotensive activities of Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Epoprostenol is combined with Argatroban.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C02CC01, bethanidine, Epoprostenol may increase the hypotensive activities of Bethanidine.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Epoprostenol.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of bleeding can be increased when Epoprostenol is combined with Belinostat.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Empagliflozin.]
[R03AC19, olodaterol, Olodaterol may decrease the antihypertensive activities of Epoprostenol.]
[L03AB13, peginterferon beta-1a, The risk or severity of bleeding can be increased when Epoprostenol is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01EE02, unoprostone, Epoprostenol may increase the hypotensive activities of Unoprostone.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05AA04, acepromazine, Acepromazine may decrease the antihypertensive activities of Epoprostenol.]
[L01BC08, decitabine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Decitabine.]
[L01EX09, nintedanib, The risk or severity of bleeding can be increased when Nintedanib is combined with Epoprostenol.]
[S03AA06, gentamicin, Epoprostenol may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, The risk or severity of bleeding can be increased when Epoprostenol is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Epoprostenol.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Epoprostenol.]
[L01EF01, palbociclib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Palbociclib.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Epoprostenol is combined with Cangrelor.]
[N05AX16, brexpiprazole, Brexpiprazole may decrease the antihypertensive activities of Epoprostenol.]
[G02CX02, flibanserin, Flibanserin may decrease the antihypertensive activities of Epoprostenol.]
[N05AX15, cariprazine, Cariprazine may decrease the antihypertensive activities of Epoprostenol.]
[M02AA25, aceclofenac, The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Epoprostenol.]
[M01AB11, acemetacin, The risk or severity of bleeding and hemorrhage can be increased when Epoprostenol is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB37, idarucizumab, Epoprostenol may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Trabectedin.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Epoprostenol.]
[L01XG03, ixazomib, Epoprostenol may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[V03AB35, sugammadex, The risk or severity of bleeding and hemorrhage can be increased when Epoprostenol is combined with Sugammadex.]
[B01AC27, selexipag, Epoprostenol may increase the hypotensive activities of Selexipag.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Epoprostenol.]
[M04AB05, lesinurad, Epoprostenol may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Epoprostenol.]
[N02BA02, aloxiprin, The risk or severity of bleeding can be increased when Aloxiprin is combined with Epoprostenol.]
[N03AX23, brivaracetam, Epoprostenol may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Epoprostenol may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, Bromocriptine may decrease the antihypertensive activities of Epoprostenol.]
[A02AD05, aluminum magnesium silicate, Epoprostenol may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Epoprostenol.]
[C08CA01, amlodipine, Epoprostenol may increase the hypotensive activities of Amlodipine.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Obeticholic acid.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Epoprostenol.]
[C07AA19, bupranolol, Epoprostenol may increase the hypotensive activities of Bupranolol.]
[N05BE01, buspirone, Buspirone may decrease the antihypertensive activities of Epoprostenol.]
[L01AB01, busulfan, The risk or severity of bleeding can be increased when Epoprostenol is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Epoprostenol.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01AA26, azithromycin, The risk or severity of adverse effects can be increased when Azithromycin is combined with Epoprostenol.]
[A07EC04, balsalazide, The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Epoprostenol.]
[R03CC12, bambuterol, Bambuterol may decrease the antihypertensive activities of Epoprostenol.]
[A06AH05, naldemedine, Epoprostenol may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Epoprostenol may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C09AA07, benazepril, Epoprostenol may increase the hypotensive activities of Benazepril.]
[P01CA02, benznidazole, Epoprostenol may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Epoprostenol.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J05AE09, tipranavir, Tipranavir may increase the antiplatelet activities of Epoprostenol.]
[H03BA03, benzylthiouracil, Benzylthiouracil may increase the anticoagulant activities of Epoprostenol.]
[N07XX13, valbenazine, Epoprostenol may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Epoprostenol.]
[J01MA23, delafloxacin, Epoprostenol may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Epoprostenol is combined with Betrixaban.]
[L01BC06, capecitabine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Capecitabine.]
[L01XH01, vorinostat, The risk or severity of bleeding can be increased when Epoprostenol is combined with Vorinostat.]
[C07AB07, bisoprolol, Epoprostenol may increase the hypotensive activities of Bisoprolol.]
[R03AC17, bitolterol, Bitolterol may decrease the antihypertensive activities of Epoprostenol.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01BA03, raltitrexed, The risk or severity of bleeding can be increased when Epoprostenol is combined with Raltitrexed.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Nesiritide.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Budesonide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Epoprostenol.]
[M01AB07, bumadizone, The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Epoprostenol.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Epoprostenol.]
[B02BX06, emicizumab, The therapeutic efficacy of Emicizumab can be decreased when used in combination with Epoprostenol.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Epoprostenol.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Epoprostenol may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, Epoprostenol may increase the hypotensive activities of Captopril.]
[L02BB05, apalutamide, Epoprostenol may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Epoprostenol may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[H03BB01, carbimazole, Carbimazole may increase the anticoagulant activities of Epoprostenol.]
[L03AB06, interferon alfa-n1, The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfa-n1.]
[C07AG02, carvedilol, Epoprostenol may increase the hypotensive activities of Carvedilol.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Epoprostenol.]
[V03AB38, andexanet alfa, The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Epoprostenol.]
[N03AX24, cannabidiol, Cannabidiol may decrease the antihypertensive activities of Epoprostenol.]
[L04AA37, baricitinib, Epoprostenol may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01GB14, plazomicin, Epoprostenol may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Epoprostenol may increase the hypotensive activities of Celiprolol.]
[A16AX14, migalastat, Epoprostenol may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Epoprostenol may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[D08AE05, chloroxylenol, Epoprostenol may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Epoprostenol.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01AD01, carmustine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Carmustine.]
[A06AX05, prucalopride, Epoprostenol may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, Epoprostenol may increase the hypotensive activities of Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Epoprostenol.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Epoprostenol.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Epoprostenol.]
[S01ED05, carteolol, Carteolol may increase the hypotensive activities of Epoprostenol.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Epoprostenol.]
[N06BA14, solriamfetol, Solriamfetol may decrease the antihypertensive activities of Epoprostenol.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C09CA06, candesartan, Epoprostenol may increase the hypotensive activities of Candesartan.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C03BX03, cicletanine, Epoprostenol may increase the hypotensive activities of Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N07XX11, pitolisant, Epoprostenol may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Epoprostenol.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[G03DB05, demegestone, The risk or severity of adverse effects can be increased when Demegestone is combined with Epoprostenol.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Trastuzumab emtansine.]
[G03AC09, desogestrel, The risk or severity of adverse effects can be increased when Desogestrel is combined with Epoprostenol.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[M09AX08, golodirsen, Epoprostenol may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Epoprostenol may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Epoprostenol.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Epoprostenol.]
[R02AA03, dichlorobenzyl alcohol, Epoprostenol may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The risk or severity of adverse effects can be increased when Dienogest is combined with Epoprostenol.]
[N02CC06, eletriptan, Eletriptan may decrease the antihypertensive activities of Epoprostenol.]
[M01AH02, rofecoxib, The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Epoprostenol.]
[L01XF03, bexarotene, The risk or severity of bleeding can be increased when Epoprostenol is combined with Bexarotene.]
[C08CA16, clevidipine, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Clevidipine.]
[C01BD07, dronedarone, Dronedarone may decrease the antihypertensive activities of Epoprostenol.]
[L01AA02, chlorambucil, The risk or severity of bleeding can be increased when Epoprostenol is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Chloramphenicol.]
[C02AA06, methoserpidine, Epoprostenol may increase the hypotensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Opicapone.]
[C01CA14, dopexamine, Dopexamine may decrease the antihypertensive activities of Epoprostenol.]
[M01AC04, droxicam, The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Epoprostenol.]
[V08CA05, mangafodipir, Epoprostenol may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Epoprostenol.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Epoprostenol.]
[C08CA17, levamlodipine, Epoprostenol may increase the hypotensive activities of Levamlodipine.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Chlorothiazide.]
[G03CA06, chlorotrianisene, Chlorotrianisene may decrease the anticoagulant activities of Epoprostenol.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the antihypertensive activities of Epoprostenol.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C03BA04, chlorthalidone, Epoprostenol may increase the hypotensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Epoprostenol.]
[N02BA03, choline salicylate, The risk or severity of bleeding can be increased when Choline salicylate is combined with Epoprostenol.]
[G03DC06, ethynodiol, The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etynodiol.]
[M01AB08, etodolac, The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Epoprostenol.]
[M02AA06, etofenamate, The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Epoprostenol.]
[L01BB05, fludarabine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Fludarabine.]
[M01AX25, chondroitin sulfates, Epoprostenol may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Epoprostenol.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Vericiguat.]
[M01AE05, fenbufen, The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Epoprostenol.]
[C01CA19, fenoldopam, Epoprostenol may increase the hypotensive activities of Fenoldopam.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Epoprostenol.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Epoprostenol.]
[J01DD08, cefixime, The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Cefixime.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N02BG07, flupirtine, Epoprostenol may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, Formoterol may decrease the antihypertensive activities of Epoprostenol.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Epoprostenol.]
[L03AB10, peginterferon alfa-2b, The risk or severity of bleeding can be increased when Epoprostenol is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Epoprostenol may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S03AA07, ciprofloxacin, Ciprofloxacin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01XA01, cisplatin, Epoprostenol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of hemorrhage can be increased when Citalopram is combined with Epoprostenol.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AB03, ioflupane I-123, Epoprostenol may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Epoprostenol may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Epoprostenol may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Epoprostenol.]
[R03CC13, clenbuterol, Clenbuterol may decrease the antihypertensive activities of Epoprostenol.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of bleeding can be increased when Epoprostenol is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The risk or severity of bleeding and thrombocytopenia can be increased when Epoprostenol is combined with Abrocitinib.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Epoprostenol is combined with Tenecteplase.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Epoprostenol.]
[N06AA04, clomipramine, Clomipramine may decrease the antihypertensive activities of Epoprostenol.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Clonidine is combined with Epoprostenol.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH02, clozapine, Clozapine may decrease the antihypertensive activities of Epoprostenol.]
[J01GB12, arbekacin, Epoprostenol may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[C02KB01, metyrosine, Epoprostenol may increase the hypotensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Epoprostenol.]
[M04AC01, colchicine, Epoprostenol may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[J01XB01, colistin, Epoprostenol may decrease the excretion rate of Colistin which could result in a higher serum level.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of bleeding can be increased when Epoprostenol is combined with Omacetaxine mepesuccinate.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N01AB07, desflurane, Desflurane may decrease the antihypertensive activities of Epoprostenol.]
[A04AA03, tropisetron, Epoprostenol may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Epoprostenol.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Epoprostenol.]
[L01BB07, nelarabine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Nelarabine.]
[B01AC10, indobufen, The risk or severity of bleeding and hemorrhage can be increased when Indobufen is combined with Epoprostenol.]
[J05AB14, valganciclovir, Epoprostenol may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Epoprostenol may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Epoprostenol may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Epoprostenol may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Epoprostenol may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Epoprostenol may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Epoprostenol.]
[A03AX10, isometheptene, Isometheptene may decrease the antihypertensive activities of Epoprostenol.]
[N02CC05, almotriptan, Almotriptan may decrease the antihypertensive activities of Epoprostenol.]
[M01AH04, parecoxib, The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Epoprostenol.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05BA10, ketazolam, Epoprostenol may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Epoprostenol.]
[L01EA01, imatinib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Imatinib.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Epoprostenol.]
[S01EE03, bimatoprost, Bimatoprost may increase the hypotensive activities of Epoprostenol.]
[C08CA09, lacidipine, Epoprostenol may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Lamotrigine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N07BC04, lofexidine, Epoprostenol may increase the hypotensive activities of Lofexidine.]
[M01AB09, lonazolac, The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Epoprostenol.]
[M02AA31, loxoprofen, The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Epoprostenol.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C09AA03, lisinopril, Epoprostenol may increase the hypotensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, Epoprostenol may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Epoprostenol may increase the hypotensive activities of Manidipine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Epoprostenol.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the antihypertensive activities of Epoprostenol.]
[C03DA04, eplerenone, Epoprostenol may increase the hypotensive activities of Eplerenone.]
[N05AD03, metylperon, Epoprostenol may decrease the excretion rate of Melperone which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The risk or severity of bleeding can be increased when Epoprostenol is combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Epoprostenol.]
[S01XA18, cyclosporine, Cyclosporine may decrease the antihypertensive activities of Epoprostenol.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Epoprostenol.]
[C09AA13, moexipril, Epoprostenol may increase the hypotensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Epoprostenol.]
[M01AX22, morniflumate, The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Epoprostenol.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC05, moxonidine, Epoprostenol may increase the hypotensive activities of Moxonidine.]
[L01BC01, cytarabine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Cytarabine.]
[G04BE09, vardenafil, Vardenafil may increase the antihypertensive activities of Epoprostenol.]
[M01AH05, etoricoxib, The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Epoprostenol.]
[L01AX04, dacarbazine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Dactinomycin.]
[L01DB02, daunorubicin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Daunorubicin.]
[C02CC04, debrisoquin, Epoprostenol may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Epoprostenol.]
[M01AX01, nabumetone, The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Epoprostenol.]
[B02BD03, anti-inhibitor coagulant complex, The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Epoprostenol.]
[N07BB05, nalmefene, Epoprostenol may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, Epoprostenol may increase the hypotensive activities of Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of hemorrhage can be increased when Nefazodone is combined with Epoprostenol.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Epoprostenol.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[G03DB04, nomegestrol, The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nomegestrol.]
[C01CA23, theodrenaline, Theodrenaline may decrease the antihypertensive activities of Epoprostenol.]
[C01CA05, norfenefrine, Norfenefrine may decrease the antihypertensive activities of Epoprostenol.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Epoprostenol is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of bleeding can be increased when Escitalopram is combined with Epoprostenol.]
[G04BD08, solifenacin, Solifenacin may decrease the antihypertensive activities of Epoprostenol.]
[A07EC03, olsalazine, The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Epoprostenol.]
[N06AA01, desipramine, Desipramine may decrease the antihypertensive activities of Epoprostenol.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Epoprostenol.]
[V04CH02, indigo carmine, Epoprostenol may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C09XA02, aliskiren, Epoprostenol may increase the hypotensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Epoprostenol.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the antihypertensive activities of Epoprostenol.]
[N06AB05, paroxetine, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Epoprostenol.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Epoprostenol.]
[C01DA05, pentaerythritol tetranitrate, Epoprostenol may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Epoprostenol may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Epoprostenol.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Epoprostenol.]
[R05DA08, pholcodine, Epoprostenol may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Epoprostenol.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C02DG01, pinacidil, Epoprostenol may increase the hypotensive activities of Pinacidil.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Pipamperone.]
[L01DC04, ixabepilone, The risk or severity of bleeding can be increased when Epoprostenol is combined with Ixabepilone.]
[R03CC07, pirbuterol, Pirbuterol may decrease the antihypertensive activities of Epoprostenol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, Diethylpropion may decrease the antihypertensive activities of Epoprostenol.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the anticoagulant activities of Epoprostenol.]
[C08CA03, isradipine, Epoprostenol may increase the hypotensive activities of Isradipine.]
[D07XC04, diflucortolone, Epoprostenol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Epoprostenol.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Epoprostenol.]
[C02DB01, dihydralazine, Epoprostenol may increase the hypotensive activities of Dihydralazine.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may decrease the anticoagulant activities of Epoprostenol.]
[C04AE04, dihydroergocristine, Dihydroergocristine may decrease the antihypertensive activities of Epoprostenol.]
[N02CA01, dihydroergotamine, Dihydroergotamine may decrease the antihypertensive activities of Epoprostenol.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of bleeding can be increased when Epoprostenol is combined with Lenalidomide.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Epoprostenol.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the anticoagulant activities of Epoprostenol.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C08DB01, diltiazem, Epoprostenol may increase the hypotensive activities of Diltiazem.]
[V03AB09, dimercaprol, Epoprostenol may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R03CC08, procaterol, Procaterol may decrease the antihypertensive activities of Epoprostenol.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Epoprostenol.]
[M01AB14, proglumetacin, The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Epoprostenol.]
[C09AA06, quinapril, Epoprostenol may increase the hypotensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Epoprostenol.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Epoprostenol.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Epoprostenol is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Epoprostenol.]
[C09AA05, ramipril, Epoprostenol may increase the hypotensive activities of Ramipril.]
[S01XA23, sirolimus, The risk or severity of bleeding can be increased when Epoprostenol is combined with Sirolimus.]
[R03CC14, reproterol, Reproterol may decrease the antihypertensive activities of Epoprostenol.]
[S01AX06, resorcinol, Epoprostenol may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05AX08, risperidone, Epoprostenol may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Epoprostenol may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Epoprostenol.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Bortezomib.]
[G04BE08, tadalafil, Epoprostenol may increase the hypotensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Epoprostenol.]
[C02KX02, ambrisentan, Epoprostenol may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Epoprostenol.]
[R03AC12, salmeterol, Salmeterol may decrease the antihypertensive activities of Epoprostenol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the antihypertensive activities of Epoprostenol.]
[C01CA04, dopamine, Dopamine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA16, dothiepin, Dosulepin may decrease the antihypertensive activities of Epoprostenol.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Epoprostenol.]
[N06AA12, doxepin, Doxepin may decrease the antihypertensive activities of Epoprostenol.]
[L01DB01, doxorubicin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Doxorubicin.]
[J01AA02, doxycycline, The risk or severity of bleeding can be increased when Doxycycline is combined with Epoprostenol.]
[N06AB06, sertraline, The risk or severity of bleeding can be increased when Sertraline is combined with Epoprostenol.]
[N01AB08, sevoflurane, Sevoflurane may decrease the antihypertensive activities of Epoprostenol.]
[N05AD08, droperidol, Droperidol may decrease the antihypertensive activities of Epoprostenol.]
[A08AA10, sibutramine, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Epoprostenol.]
[A12CA02, sodium sulfate, Epoprostenol may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Epoprostenol may increase the hypotensive activities of Spirapril.]
[G03DB01, dydrogesterone, Dydrogesterone may decrease the anticoagulant activities of Epoprostenol.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N02CC01, sumatriptan, Sumatriptan may decrease the antihypertensive activities of Epoprostenol.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C07AB13, talinolol, Epoprostenol may increase the hypotensive activities of Talinolol.]
[J01CG02, tazobactam, The risk or severity of bleeding can be increased when Tazobactam is combined with Epoprostenol.]
[L01AX03, temozolomide, The risk or severity of bleeding can be increased when Epoprostenol is combined with Temozolomide.]
[M01AC02, tenoxicam, The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Epoprostenol.]
[G04CA03, terazosin, Epoprostenol may increase the hypotensive activities of Terazosin.]
[S01GA02, tetrahydrozoline, Tetryzoline may decrease the antihypertensive activities of Epoprostenol.]
[N06AX14, tianeptine, Tianeptine may decrease the antihypertensive activities of Epoprostenol.]
[G03CX01, tibolone, Tibolone may increase the anticoagulant activities of Epoprostenol.]
[C09AA02, enalapril, Epoprostenol may increase the hypotensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Epoprostenol.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Epoprostenol.]
[N06BA09, atomoxetine, Atomoxetine may decrease the antihypertensive activities of Epoprostenol.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of bleeding can be increased when Toremifene is combined with Epoprostenol.]
[C03CA04, torsemide, Epoprostenol may increase the hypotensive activities of Torasemide.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Epoprostenol.]
[C09AA10, trandolapril, Epoprostenol may increase the hypotensive activities of Trandolapril.]
[N05CC01, chloral hydrate, Epoprostenol may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Epoprostenol is combined with Triflusal.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Troxerutin.]
[R03CC11, tulobuterol, Tulobuterol may decrease the antihypertensive activities of Epoprostenol.]
[C02CA06, urapidil, Epoprostenol may increase the hypotensive activities of Urapidil.]
[L01CA04, vinorelbine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Vinorelbine.]
[S01FB02, ephedrine, Ephedrine may decrease the antihypertensive activities of Epoprostenol.]
[N06AX16, venlafaxine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Venlafaxine.]
[C01CX07, xamoterol, Xamoterol may decrease the antihypertensive activities of Epoprostenol.]
[S01GA03, xylometazoline, Xylometazoline may decrease the antihypertensive activities of Epoprostenol.]
[C08CA12, mepirodipine, Epoprostenol may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, Epinephrine may decrease the antihypertensive activities of Epoprostenol.]
[L01DB03, epirubicin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Epirubicin.]
[C09AA15, zofenopril, Epoprostenol may increase the hypotensive activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Epoprostenol.]
[N03AX15, zonisamide, Zonisamide may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Epoprostenol is combined with Anistreplase.]
[L01XA02, carboplatin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Carboplatin.]
[C02AC02, guanfacine, Epoprostenol may increase the hypotensive activities of Guanfacine.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Epoprostenol.]
[G02AB03, ergonovine, Ergometrine may decrease the antihypertensive activities of Epoprostenol.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may decrease the antihypertensive activities of Epoprostenol.]
[N02CA02, ergotamine, Ergotamine may decrease the antihypertensive activities of Epoprostenol.]
[L03AX05, pidotimod, Epoprostenol may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of bleeding can be increased when Erythromycin is combined with Epoprostenol.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[G03CA03, estradiol, The risk or severity of adverse effects can be increased when Estradiol is combined with Epoprostenol.]
[G03CC06, estriol, Estriol may decrease the anticoagulant activities of Epoprostenol.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the anticoagulant activities of Epoprostenol.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C01CA15, gepefrine, Gepefrine may decrease the antihypertensive activities of Epoprostenol.]
[L02AA03, ethinyl estradiol, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Epoprostenol.]
[V03AF05, amifostine, Epoprostenol may increase the hypotensive activities of Amifostine.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[M01AC06, meloxicam, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Epoprostenol.]
[C01CA01, etilefrine, Etilefrine may decrease the antihypertensive activities of Epoprostenol.]
[N01AX07, etomidate, Etomidate may decrease the antihypertensive activities of Epoprostenol.]
[L01CB01, etoposide, The risk or severity of bleeding can be increased when Epoprostenol is combined with Etoposide.]
[L04AD02, tacrolimus, The risk or severity of bleeding can be increased when Epoprostenol is combined with Tacrolimus.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AX12, bupropion, Bupropion may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AB08, fluvoxamine, The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Epoprostenol.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Epoprostenol may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B02BD08, factor VIIa, The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Epoprostenol.]
[B02BD14, antihemophilic factor, porcine B-domain truncated recombinant, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Epoprostenol.]
[A05AA01, chenodeoxycholic acid, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Chenodeoxycholic acid.]
[D11AX24, deoxycholic acid, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Deoxycholic acid.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Epoprostenol is combined with Dextran.]
[B02BD11, coagulation factor XIII a-subunit (recombinant), The therapeutic efficacy of Catridecacog can be decreased when used in combination with Epoprostenol.]
[B02BD07, factor XIII, The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Epoprostenol.]
[V03AF02, dexrazoxane, The risk or severity of bleeding can be increased when Epoprostenol is combined with Dexrazoxane.]
[A16AA01, levocarnitine, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Levocarnitine.]
[C08CA02, felodipine, Epoprostenol may increase the hypotensive activities of Felodipine.]
[M01AE04, fenoprofen, The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Epoprostenol.]
[R03CC04, fenoterol, Fenoterol may decrease the antihypertensive activities of Epoprostenol.]
[N02AB03, fentanyl, Fentanyl may decrease the antihypertensive activities of Epoprostenol.]
[R03CC02, albuterol, Salbutamol may decrease the antihypertensive activities of Epoprostenol.]
[B02BB01, fibrinogen, human, The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Epoprostenol.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Epoprostenol.]
[L04AA40, cladribine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Cladribine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Epoprostenol.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J02AX01, flucytosine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Flucytosine.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Epoprostenol.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Epoprostenol.]
[L01BC09, floxuridine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Floxuridine.]
[L01BC02, fluorouracil, The risk or severity of bleeding can be increased when Epoprostenol is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Epoprostenol.]
[N05AF01, flupenthixol, Flupentixol may decrease the antihypertensive activities of Epoprostenol.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Epoprostenol.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01BC03, tegafur, Epoprostenol may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, Adrafinil may decrease the antihypertensive activities of Epoprostenol.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Epoprostenol.]
[C03CA01, furosemide, Epoprostenol may increase the hypotensive activities of Furosemide.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Epoprostenol.]
[C10AB04, gemfibrozil, Epoprostenol may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Epoprostenol may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Epoprostenol.]
[N04BC06, cabergoline, Cabergoline may decrease the antihypertensive activities of Epoprostenol.]
[G03XA02, gestrinone, The risk or severity of adverse effects can be increased when Gestrinone is combined with Epoprostenol.]
[L02AB03, gestronol, Gestonorone may decrease the anticoagulant activities of Epoprostenol.]
[N01AH02, alfentanil, Alfentanil may decrease the antihypertensive activities of Epoprostenol.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[M01AX05, glucosamine, Glucosamine may increase the antiplatelet activities of Epoprostenol.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the antihypertensive activities of Epoprostenol.]
[C05AE01, nitroglycerin, Epoprostenol may increase the hypotensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Epoprostenol may increase the hypotensive activities of Doxazosin.]
[L01EX02, sorafenib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Sorafenib.]
[C07AB09, esmolol, Epoprostenol may increase the hypotensive activities of Esmolol.]
[M01CB04, aurothioglucose, Epoprostenol may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Epoprostenol may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Epoprostenol is combined with Fluindione.]
[C09AA09, fosinopril, Epoprostenol may increase the hypotensive activities of Fosinopril.]
[S01EX01, guanethidine, Epoprostenol may increase the hypotensive activities of Guanethidine.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05AD01, haloperidol, Haloperidol may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N01AB01, halothane, Halothane may decrease the antihypertensive activities of Epoprostenol.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Epoprostenol.]
[N06BX13, idebenone, Epoprostenol may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[L01CE02, irinotecan, The risk or severity of bleeding can be increased when Epoprostenol is combined with Irinotecan.]
[B06AB01, hemin, Hemin may increase the anticoagulant activities of Epoprostenol.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C09CA01, losartan, Epoprostenol may increase the hypotensive activities of Losartan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Heparin.]
[G03DC01, allylestrenol, Allylestrenol may decrease the anticoagulant activities of Epoprostenol.]
[A07EC02, mesalamine, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Epoprostenol.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Altretamine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Epoprostenol.]
[R03CC05, hexoprenaline, Hexoprenaline may decrease the antihypertensive activities of Epoprostenol.]
[C08CA10, nilvadipine, Epoprostenol may increase the hypotensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Epoprostenol.]
[C09AA04, perindopril, Epoprostenol may increase the hypotensive activities of Perindopril.]
[C02DB02, hydralazine, Epoprostenol may increase the hypotensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Epoprostenol may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[G04BD06, propiverine, Propiverine may decrease the antihypertensive activities of Epoprostenol.]
[B05AA07, hetastarch, Epoprostenol may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[G03DA03, 17-alpha-hydroxyprogesterone, Hydroxyprogesterone may decrease the anticoagulant activities of Epoprostenol.]
[L01XX05, hydroxyurea, The risk or severity of bleeding can be increased when Epoprostenol is combined with Hydroxyurea.]
[C02AC06, rilmenidine, Epoprostenol may increase the hypotensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of bleeding can be increased when Ibuprofen is combined with Epoprostenol.]
[B05XA08, sodium acetate, Epoprostenol may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Epoprostenol is combined with Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of bleeding can be increased when Ifosfamide is combined with Epoprostenol.]
[N01AH03, sufentanil, Sufentanil may decrease the antihypertensive activities of Epoprostenol.]
[N06AA02, imipramine, Imipramine may decrease the antihypertensive activities of Epoprostenol.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Epoprostenol.]
[R01AD07, tixocortol, Epoprostenol may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Epoprostenol.]
[L01CE01, topotecan, The risk or severity of bleeding can be increased when Epoprostenol is combined with Topotecan.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Epoprostenol.]
[S01BC01, indomethacin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Epoprostenol.]
[C02CA02, indoramin, Epoprostenol may increase the hypotensive activities of Indoramin.]
[A11HA07, inositol, Epoprostenol may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of hemorrhage can be increased when Milnacipran is combined with Epoprostenol.]
[D03BA02, collagenase, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Collagenase clostridium histolyticum.]
[S01XA28, varenicline, Epoprostenol may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[A10BH01, sitagliptin, Epoprostenol may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Epoprostenol.]
[C07AA01, alprenolol, Epoprostenol may increase the hypotensive activities of Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfacon-1.]
[V03AB01, ipecac, Epoprostenol may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Epoprostenol.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Epoprostenol.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Epoprostenol.]
[S01EC03, dorzolamide, Dorzolamide may increase the hypotensive activities of Epoprostenol.]
[R03CC06, isoetharine, Isoetharine may decrease the antihypertensive activities of Epoprostenol.]
[C09AA16, imidapril, Epoprostenol may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may decrease the antihypertensive activities of Epoprostenol.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J05AX05, inosine pranobex, Epoprostenol may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, Isoprenaline may decrease the antihypertensive activities of Epoprostenol.]
[C01DA14, isosorbide mononitrate, Epoprostenol may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Epoprostenol.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C04AA01, isoxsuprine, Isoxsuprine may decrease the antihypertensive activities of Epoprostenol.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Bivalirudin.]
[C04AF01, kininogenase, The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Epoprostenol.]
[S01AA24, kanamycin, Epoprostenol may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, Ketamine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Epoprostenol.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Epoprostenol is combined with Prasugrel.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Epoprostenol.]
[M02AA10, ketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Epoprostenol.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding can be increased when Epoprostenol is combined with Deferasirox.]
[C01CA22, arbutamine, Arbutamine may decrease the antihypertensive activities of Epoprostenol.]
[N04BC09, rotigotine, Rotigotine may decrease the antihypertensive activities of Epoprostenol.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Epoprostenol.]
[C07AG01, labetalol, Epoprostenol may increase the hypotensive activities of Labetalol.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C02AA05, deserpidine, Epoprostenol may increase the hypotensive activities of Deserpidine.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A05AA02, ursodiol, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ursodeoxycholic acid.]
[L01DC03, mitomycin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Mitomycin.]
[G03AD01, levonorgestrel, The risk or severity of adverse effects can be increased when Levonorgestrel is combined with Epoprostenol.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Epoprostenol is combined with Levodopa.]
[S01AA21, amikacin, Epoprostenol may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, Lisuride may decrease the antihypertensive activities of Epoprostenol.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Epoprostenol.]
[L01AD02, lomustine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Lomustine.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[G03DC03, lynestrenol, The risk or severity of adverse effects can be increased when Lynestrenol is combined with Epoprostenol.]
[L01EG01, temsirolimus, The risk or severity of bleeding can be increased when Epoprostenol is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Epoprostenol may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Epoprostenol may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[L01BA05, pralatrexate, Epoprostenol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of bleeding can be increased when Epoprostenol is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C02BB01, mecamylamine, Epoprostenol may increase the hypotensive activities of Mecamylamine.]
[L01AA05, mechlorethamine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Mechlorethamine.]
[M02AA18, meclofenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Epoprostenol.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Epoprostenol.]
[G03DB03, medrogestone, Medrogestone may decrease the anticoagulant activities of Epoprostenol.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Dalteparin.]
[L01AA03, melphalan, The risk or severity of bleeding can be increased when Epoprostenol is combined with Melphalan.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C01CA11, mephentermine, Mephentermine may decrease the antihypertensive activities of Epoprostenol.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Epoprostenol.]
[N01BB03, mepivacaine, Mepivacaine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[G04BX16, tiopronin, Epoprostenol may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Paliperidone may decrease the antihypertensive activities of Epoprostenol.]
[C01CA09, metaraminol, Metaraminol may decrease the antihypertensive activities of Epoprostenol.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N07BC02, methadone, Methadone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06BA03, methamphetamine, Metamfetamine may decrease the antihypertensive activities of Epoprostenol.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, Metergoline may decrease the antihypertensive activities of Epoprostenol.]
[H03BB02, methimazole, Methimazole may increase the anticoagulant activities of Epoprostenol.]
[L01BA04, pemetrexed, Epoprostenol may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Epoprostenol.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of bleeding can be increased when Epoprostenol is combined with Methotrexate.]
[N05AA02, methotrimeprazine, Methotrimeprazine may decrease the antihypertensive activities of Epoprostenol.]
[C01CA10, methoxamine, Methoxamine may decrease the antihypertensive activities of Epoprostenol.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N02BG09, methoxyflurane, Methoxyflurane may decrease the antihypertensive activities of Epoprostenol.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, Epoprostenol may increase the hypotensive activities of Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Epoprostenol.]
[G02AB01, methylergonovine, Methylergometrine may decrease the antihypertensive activities of Epoprostenol.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Epoprostenol.]
[G03EK01, methyltestosterone, Epoprostenol may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, Methysergide may decrease the antihypertensive activities of Epoprostenol.]
[A03FA01, metoclopramide, Metoclopramide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C03BA08, metolazone, Epoprostenol may increase the hypotensive activities of Metolazone.]
[C07AB02, metoprolol, Epoprostenol may increase the hypotensive activities of Metoprolol.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Epoprostenol.]
[N02BB03, aminopyrine, The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Epoprostenol.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Parnaparin.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C01CA17, midodrine, Midodrine may decrease the antihypertensive activities of Epoprostenol.]
[G03XB01, mifepristone, The risk or severity of adverse effects can be increased when Mifepristone is combined with Epoprostenol.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Tinzaparin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C09CA03, valsartan, Epoprostenol may increase the hypotensive activities of Valsartan.]
[D11AX01, minoxidil, Epoprostenol may increase the hypotensive activities of Minoxidil.]
[L01DB07, mitoxantrone, The risk or severity of bleeding can be increased when Epoprostenol is combined with Mitoxantrone.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the antihypertensive activities of Epoprostenol.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Epoprostenol.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Epoprostenol.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Epoprostenol.]
[N06AA09, amitriptyline, Amitriptyline may decrease the antihypertensive activities of Epoprostenol.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Epoprostenol.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Epoprostenol may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Epoprostenol may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Epoprostenol.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Epoprostenol is combined with Silodosin.]
[N06AA17, amoxapine, Amoxapine may decrease the antihypertensive activities of Epoprostenol.]
[L03AB08, interferon beta-1b, The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon beta-1b.]
[C07AA12, nadolol, Epoprostenol may increase the hypotensive activities of Nadolol.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Epoprostenol.]
[V03AB15, naloxone, Naloxone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[S01GA01, naphazoline, Naphazoline may decrease the antihypertensive activities of Epoprostenol.]
[N06BA01, amphetamine, Amphetamine may decrease the antihypertensive activities of Epoprostenol.]
[M02AA12, naproxen, The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Epoprostenol.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Epoprostenol is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Epoprostenol.]
[L01CD02, docetaxel, The risk or severity of bleeding can be increased when Epoprostenol is combined with Docetaxel.]
[S03AA01, neomycin, Epoprostenol may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, Remifentanil may decrease the antihypertensive activities of Epoprostenol.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Epoprostenol.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Epoprostenol.]
[N05AX14, iloperidone, Iloperidone may decrease the antihypertensive activities of Epoprostenol.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Epoprostenol.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[L03AX16, plerixafor, Epoprostenol may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Epoprostenol may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Epoprostenol.]
[C09CA07, telmisartan, Epoprostenol may increase the hypotensive activities of Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C01CE01, inamrinone, Epoprostenol may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Amsacrine.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Epoprostenol.]
[C08CA04, nicardipine, Epoprostenol may increase the hypotensive activities of Nicardipine.]
[C04AE02, nicergoline, Nicergoline may decrease the antihypertensive activities of Epoprostenol.]
[C08CA05, nifedipine, The risk or severity of adverse effects can be increased when Nifedipine is combined with Epoprostenol.]
[M02AA17, niflumic acid, The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Epoprostenol.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Epoprostenol may increase the hypotensive activities of Nimodipine.]
[C08CA07, nisoldipine, Epoprostenol may increase the hypotensive activities of Nisoldipine.]
[C08CA08, nitrendipine, Epoprostenol may increase the hypotensive activities of Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Epoprostenol.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Epoprostenol.]
[C02DD01, nitroprusside, Epoprostenol may increase the hypotensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Epoprostenol.]
[C01CA03, norepinephrine, Norepinephrine may decrease the antihypertensive activities of Epoprostenol.]
[G03DC02, norethindrone, The risk or severity of adverse effects can be increased when Norethisterone is combined with Epoprostenol.]
[G03AC07, norgestrienone, The risk or severity of adverse effects can be increased when Norgestrienone is combined with Epoprostenol.]
[C02KX01, bosentan, Epoprostenol may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may decrease the antihypertensive activities of Epoprostenol.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Epoprostenol.]
[G02CA02, nylidrin, Nylidrin may decrease the antihypertensive activities of Epoprostenol.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Epoprostenol is combined with Reviparin.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Epoprostenol.]
[N02AA02, opium, Epoprostenol may decrease the excretion rate of Opium which could result in a higher serum level.]
[R03CB03, metaproterenol, Orciprenaline may decrease the antihypertensive activities of Epoprostenol.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Epoprostenol is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Epoprostenol is combined with Ancrod.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Tamsulosin is combined with Epoprostenol.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C07AA02, oxprenolol, Epoprostenol may increase the hypotensive activities of Oxprenolol.]
[C01DX03, oxyfedrine, Oxyfedrine may decrease the antihypertensive activities of Epoprostenol.]
[S01GA04, oxymetazoline, Oxymetazoline may decrease the antihypertensive activities of Epoprostenol.]
[S01BC02, oxyphenbutazone, The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Epoprostenol.]
[J04AA01, aminosalicylic acid, The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Epoprostenol.]
[N05AH05, asenapine, Asenapine may decrease the antihypertensive activities of Epoprostenol.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Epoprostenol is combined with Danaparoid.]
[J04AB30, capreomycin, Epoprostenol may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The risk or severity of adverse effects can be increased when Chlormadinone is combined with Epoprostenol.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Epoprostenol.]
[C02KC01, pargyline, Epoprostenol may increase the hypotensive activities of Pargyline.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[G04BD11, fesoterodine, Epoprostenol may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Epoprostenol may increase the hypotensive activities of Penbutolol.]
[M01CC01, penicillamine, The risk or severity of bleeding can be increased when Epoprostenol is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Epoprostenol may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Epoprostenol.]
[L01XX08, pentostatin, Epoprostenol may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Pentoxifylline.]
[N04BC02, pergolide, Pergolide may decrease the antihypertensive activities of Epoprostenol.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Epoprostenol.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Epoprostenol is combined with Phenindione.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Epoprostenol.]
[C04AX02, phenoxybenzamine, Epoprostenol may increase the hypotensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Epoprostenol is combined with Phenprocoumon.]
[A08AA01, phentermine, Phentermine may decrease the antihypertensive activities of Epoprostenol.]
[V03AB36, phentolamine, Epoprostenol may increase the hypotensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Epoprostenol.]
[S01GA05, phenylephrine, Phenylephrine may decrease the antihypertensive activities of Epoprostenol.]
[R01BA01, phenylpropanolamine, Phenylpropanolamine may decrease the antihypertensive activities of Epoprostenol.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C08CX01, mibefradil, Epoprostenol may increase the hypotensive activities of Mibefradil.]
[C07AA03, pindolol, Epoprostenol may increase the hypotensive activities of Pindolol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06BX03, piracetam, Epoprostenol may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Epoprostenol may increase the hypotensive activities of Eprosartan.]
[S01BC06, piroxicam, The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Epoprostenol.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N02CX01, pizotyline, Pizotifen may decrease the antihypertensive activities of Epoprostenol.]
[C09CA04, irbesartan, Epoprostenol may increase the hypotensive activities of Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Epoprostenol.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Epoprostenol is combined with Alteplase.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C03AA05, polythiazide, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Polythiazide.]
[A10BH03, saxagliptin, Epoprostenol may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[V03AB21, potassium iodide, Potassium Iodide may increase the anticoagulant activities of Epoprostenol.]
[C07AB01, practolol, Epoprostenol may increase the hypotensive activities of Practolol.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Epoprostenol.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Epoprostenol.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C01BA02, procainamide, Epoprostenol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Epoprostenol.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Epoprostenol.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[G03DA04, progesterone, The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Progesterone.]
[N05AA03, promazine, Promazine may decrease the antihypertensive activities of Epoprostenol.]
[G03DB07, promegestone, Promegestone may decrease the anticoagulant activities of Epoprostenol.]
[R06AD02, promethazine, Promethazine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C01BC03, propafenone, Propafenone may decrease the antihypertensive activities of Epoprostenol.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N05AC01, periciazine, Periciazine may decrease the antihypertensive activities of Epoprostenol.]
[N05CM06, propiomazine, Propiomazine may decrease the antihypertensive activities of Epoprostenol.]
[N01AX10, propofol, Propofol may decrease the antihypertensive activities of Epoprostenol.]
[C07AA05, propranolol, Epoprostenol may increase the hypotensive activities of Propranolol.]
[H03BA02, propylthiouracil, Propylthiouracil may increase the anticoagulant activities of Epoprostenol.]
[N02CC04, rizatriptan, Rizatriptan may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, Protriptyline may decrease the antihypertensive activities of Epoprostenol.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the antihypertensive activities of Epoprostenol.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Epoprostenol.]
[N07XX07, dalfampridine, Epoprostenol may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Epoprostenol may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[M09AB02, collagenase Clostridium histolyticum, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Collagenase clostridium histolyticum.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C01BA01, quinidine, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Quinidine.]
[P01BC01, quinine, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Quinine.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[C02AA01, rescinnamine, Epoprostenol may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, Epoprostenol may increase the hypotensive activities of Reserpine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03AC05, rimiterol, Rimiterol may decrease the antihypertensive activities of Epoprostenol.]
[G02CA01, ritodrine, Ritodrine may decrease the antihypertensive activities of Epoprostenol.]
[N02BA05, salicylamide, The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Epoprostenol.]
[A07EC01, sulfasalazine, The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Epoprostenol.]
[S01BC08, salicylic acid, The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Epoprostenol.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Epoprostenol.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Epoprostenol.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Obinutuzumab.]
[J01GB08, sisomicin, Epoprostenol may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Epoprostenol may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Epoprostenol may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Epoprostenol.]
[L01CD04, cabazitaxel, The risk or severity of bleeding can be increased when Epoprostenol is combined with Cabazitaxel.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
